Gilead Sciences v. Macleods: HIV Patent Consent Judgment
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Gilead Sciences, Inc. v. Macleods Pharmaceuticals Ltd. |
| Numéro de dossier | 1:26-cv-00094 (D. Del.) |
| Tribunal | Tribunal fédéral de première instance pour le district du Delaware |
| Durée | Feb 2026 – Feb 2026 27 days |
| Résultat | Plaintiff Win — Consent Judgment & Injunctive Relief |
| Brevets en cause | |
| Produits incriminés | Macleods’ generic TAF-based product (ANDA No. 220967) |
Aperçu du dossier
Les parties
⚖️ Demandeur
Global biopharmaceutical leader with one of the most formidable antiviral IP portfolios in the industry. VEMLIDY® (TAF) is a cornerstone product generating significant revenue across HIV and hepatitis treatment markets.
🛡️ Défendeur
India-headquartered generic pharmaceutical manufacturer with a growing ANDA pipeline targeting U.S. markets. Macleods sought regulatory approval for a generic TAF-based product.
Brevets en cause
This landmark pharmaceutical case involved two foundational patents protecting Gilead’s VEMLIDY® (tenofovir alafenamide, “TAF”) — a cornerstone antiviral therapy. Both patents protect critical aspects of the TAF molecule and its pharmaceutical application.
- • U.S. Patent No. 8,754,065 — Covering core chemical composition and formulation claims related to tenofovir alafenamide compounds
- • U.S. Patent No. 9,296,769 — Covering related structural or method-of-treatment claims within the TAF therapeutic framework
Vous développez une formulation médicamenteuse similaire ?
Check if your drug formulation might infringe these or related patents before launch.
Le verdict et l'analyse juridique
Résultat
The parties entered a Consent Judgment and Order on February 24, 2026, resolving all claims by mutual agreement. The court formally asserted and retained jurisdiction, dismissed all defenses without prejudice, and issued a permanent injunction barring Macleods and its affiliates from commercializing their generic TAF product until an agreed-upon, confidential date. No damages were awarded publicly, and both parties waived appellate rights.
Principales questions juridiques
The rapid 27-day resolution indicates early settlement negotiations were likely underway. The infringement action was predicated on Macleods’ ANDA filing — a constructive act of infringement under 35 U.S.C. § 271(e)(2). This is the standard legal mechanism in Hatch-Waxman cases, enabling brand manufacturers to seek injunctive relief before generic market entry. While no legal questions were decided on the merits and no claim construction was issued, the outcome signals the continued strength of Gilead’s TAF patent estate and their aggressive enforcement posture.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in antiviral drug development. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige pharmaceutique.
- View all related patents in the HIV/TAF space
- See which companies are most active in antiviral IP
- Understand claim construction patterns for TAF
🔍 Vérifier les risques liés à mon produit
Réalisez une analyse FTO complète pour votre propre formulation médicamenteuse ou votre produit thérapeutique.
- Saisissez la description de votre médicament ou ses caractéristiques techniques
- L'IA identifie les brevets pharmaceutiques susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Tenofovir Alafenamide (TAF) formulations
Gilead’s TAF Portfolio
Multiple patents, strong enforcement
Options de contournement
Complex, but possible with deep analysis
✅ Points clés à retenir
Consent judgments with confidential market entry dates are common in Hatch-Waxman, streamlining market entry without full trial.
Rechercher la jurisprudence connexe →A rapid 27-day resolution suggests strong incentives for early settlement from both sides in pharmaceutical patent disputes.
Explorer les précédents →Foire aux questions
The case involved U.S. Patent Nos. 8,754,065 and 9,296,769, both protecting aspects of tenofovir alafenamide (TAF), the active ingredient in Gilead’s VEMLIDY® antiviral therapy.
The parties entered a mutual consent judgment including a permanent injunction against Macleods’ ANDA No. 220967, with a confidential agreed market entry date. No merits determination was made.
The case reinforces Gilead’s ability to secure injunctive relief rapidly in ANDA disputes and signals the continued strength of the TAF patent estate as a deterrent to full-scale validity challenges.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- U.S. Patent and Trademark Office — Patent 8,754,065
- U.S. Patent and Trademark Office — Patent 9,296,769
- U.S. District Court for the District of Delaware — Case 1:26-cv-00094
- Gilead Sciences, Inc. Corporate Website — VEMLIDY®
- PatSnap — Pharmaceutical IP Solutions
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.